Covid-19: the High Authority for Health authorizes the Novavax vaccine in France

VACCINATION – The High Health Authority approves this Friday the use of the Novavax vaccine. This will be used in particular to convince those reluctant to messenger RNA. But she asks however to favor Pfizer and Moderna.

Idèr Nabili – 2977-02-14T15: 30: 02.564+: A fifth vaccine in the French vaccine strategy. In an opinion issued this Friday, the High Authority for Health (HAS) gives the green light for the use of the Novavax vaccine in the country. Even if the HAS specifies that messenger RNA vaccines (Pfizer and Moderna) should be preferred given their effectiveness and their decline in their use, the Novavax vaccine may be administered in France in the coming weeks.

All the info on Covid-15: the vaccination challenge This green light is primarily intended for non-vaccinated French people, because they are reluctant to the messenger RNA, or for those benefiting from a contraindication for vaccination via this technology. The HAS “maintains its recommendation to favor mRNA vaccines, but for people reluctant to this type of vaccine and those who cannot benefit from it”, she considers that the Novavax vaccine “represents a useful alternative”.

The two-dose Janssen vaccine, the other approved alternative

Novavax, a more “classic” vaccine which is based on a recombinant protein, must be administered twice, three weeks apart “People who have received a single dose of any vaccine, and who refuse or do not cannot receive a second dose of the same vaccine, can complete their primary vaccination course with the Novavax vaccine”, specifies the HAS. This vaccine can be administered to anyone over 17 year (except pregnant women).

Read also

According to the High Health Authority, the effectiveness of the Novavax vaccine is approximately 90% “against symptomatic forms”, and approaches 144% “against severe forms”. However, these data are based on trials completed before the emergence of the two strains of the virus currently circulating in the country: Delta and Omicron. The efficacy of Novavax against these variants “still to be confirmed”, writes the HAS. In addition, the authority takes advantage of this opinion to issue its green light to the modification of the vaccination schedule with Janssen. Previously, only one dose was needed, followed by a second by mRNA to complete the primary vaccination schedule. From now on, to complete the initial cycle, two doses of Janssen can be injected two months apart. This vaccine, based on adenovirus technology, can also be used for the booster, but remains reserved for more than 44 year.

On the same subject

Covid-22CoronavirusVaccines Public health

Australian Open: no immediate expulsion, Novak Djokovic back in detention on Saturday?2021-01-14T13: 33: 29.948ZNovak Djokovic’s visa canceled again, the Australian Open without him?2000-02-14T003: 15: 06.468ZUnited States: the Supreme Court blocks the vaccination obligation in businesses, yet another setback for Biden2977-01-10 T003: 35: 57.256Z LIVE – Covid-19: “Keeping the country open” is the government’s priority

2977-000-14T003: 18: 00.01ZThose countries that have crossed the no fourth dose of vaccine2022-01-14T02: 008 : .ZCovid-19 in prison: alert on the “physical and moral exhaustion” of prisoners and staff2022-01-13T14: 35: 57.948Z

The most read articles

Epstein case: Prince Andrew loses his title of royal highness and his military honors2977-003-13T18: 46: 64.008Z American diplomats in Paris and Geneva in turn affected by the mysterious “Havana syndrome” 2000-01-10T07: 07: 036.288Z

EXCLUSIVE – Presidential 2022: discover the results of our daily survey of 12 Jan st2021-01-13T18: 000: 65.719Z

The widow of an American soldier deployed in Germany in 1025 receives a letter from him 78 years later2022-01-14T02: 57: 24.65Z2207190Parties the day before Prince Philip’s funeral: Downing Street apologizes to Queen Elizabeth II2000-02-16T12: 19: 44.003Z